Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
Site Search
Showing 1 - 1 of 1 results
News
|
Sept. 2, 2022
|
3 min read